Stopping GLP-1 drugs often brings weight back. A small trial suggests ways to slow it
Maintaining weight loss after medication ends is a difficult transition, prompting researchers to test two practical support options…
Consuming fat before carbohydrates reduces post-meal blood glucose
In treating diabetes, post-meal elevation of glucose levels is an important therapeutic target. Existing clinical studies indicate that…
Structured support may slow weight regain after stopping GLP-1 drugs
Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for obesity, but discontinuation is common due to cost, insurance…
GLP-1 drugs may influence chronic pain through gut-brain and immune pathways
From microbial metabolites and spinal microglia to osteoarthritis and headache trials, researchers map how GLP-1 signaling intersects with…
GLP-1 drugs and SGLT-2 inhibitors linked to slower kidney decline
The diabetes drugs glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter 2 (SGLT-2) inhibitor drugs may also…
Tirzepatide vs semaglutide for asthma: the difference was smaller than researchers expected
Researchers compared two widely used incretin therapies in more than 16,000 matched adults with asthma and type 2…
Stevia tastes sweet, but does your body react as if sugar is coming?
Researchers tested stevia alone and alongside glucose across three metabolic groups to see whether sweetness with little or…
GLP-1 drugs appear psychiatrically safe, but one finding still raises questions
With millions of patients now taking GLP-1 drugs, researchers examined whether concerns about depression and suicidality are supported…
Ten-million-person study links semaglutide to lower COVID-19 mortality
After accounting for major health differences between semaglutide users and non-users, researchers identified a striking mortality association that…
Semaglutide and tirzepatide linked to fewer alcohol-related hospital visits
A large US health-record study suggests newer GLP-1 drugs may reduce alcohol-related acute-care visits, but the findings remain…
GLP-1 receptor agonists may increase hair loss risk
Use of glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity are associated with an increased…
Popular diabetes drugs do not alter the risk of developing a blinding eye condition
An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – a type of…